Table 1.
Currently approved immune checkpoint inhibitors
| Generic name | Trade name | Target | Indication (approval year) |
|---|---|---|---|
| Pembrolizumab | Keytruda | PD-1[2] | Melanoma, nonsmall cell lung cancer (2018), head and neck squamous cell cancer (2018), classical Hodgkin lymphoma (2018), primary mediastinal large B-cell lymphoma (2018), urothelial carcinoma (2018), microsatellite instability-high cancer (2018), gastric cancer (2018), cervical cancer (2018), hepatocellular carcinoma (2018), Merkel cell carcinoma (2018)[2,3] |
| Nivolumab | Opdivo | PD-1[4] | Metastatic small cell lung cancer (2018), unresectable or metastatic melanoma (2017), locally advanced or metastatic urothelial carcinoma (2017), adult and pediatric patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (2017), hepatocellular carcinoma (2017), metastatic nonsmall cell lunch cancer (2016), advanced renal cell carcinoma (2016), classical Hodgkin lymphoma (2016), recurrent or metastatic squamous cell carcinoma of the head and neck (2016)[3,4] |
| Cemiplimab | Libtayo | PD-1[5] | Metastatic cutaneous squamous cell carcinoma (2018), locally advanced CSCC (2018)[3,5] |
| Atezolizumab | Tecentriq | PD-L1[6] | Urothelial carcinoma (2016), metastatic nonsmall cell lung cancer (2016)[3,6] |
| Avelumab | Bavencio | PD-L1[7] | Metastatic Merkel cell carcinoma (2017), locally advanced or metastatic urothelial carcinoma (2017)[3,7] |
| Durvalumab | Imfinzi | PD-L1[8] | Unresectable Stage III nonsmall cell lung cancer (2018), locally advanced or metastatic urothelial carcinoma (2017)[3,8] |
| Ipilimumab | Yervoy | CTLA-4[9] | Advanced renal cell carcinoma (2018), adults and pediatric with microsatellite instability-high or mismatch repair-deficient (2018) metastatic colorectal cancer (2018), cutaneous melanoma (2015), unresectable or metastatic melanoma (2014)[3,9] |
CSCC: Cutaneous squamous cell carcinoma